Thomas Balligand

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.

S. Kubicek, R. Kralovics, R. Lesyk, 2020, Blood.

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

D. Vertommen, C. Pecquet, W. Vainchenker, 2019, Blood.

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers

C. Pecquet, J. Staerk, Steven O. Smith, 2023, eLife.

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development

C. Pecquet, S. Constantinescu, W. Vainchenker, 2019, Leukemia.

An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections

H. Ploegh, Xin Liu, Claire Carpenet, 2023, Science Immunology.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis

F. Pasquier, W. Vainchenker, H. Raslova, 2017, Haematologica.

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

C. Pecquet, A. Shiau, A. Dusa, 2019, The Journal of allergy and clinical immunology.

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

M. Cazzola, C. Pecquet, W. Vainchenker, 2018, Blood.

Molecular Identification of Hydroxylysine Kinase and of Ammoniophospholyases Acting on 5-Phosphohydroxy-l-lysine and Phosphoethanolamine*

M. Veiga-da-Cunha, E. Van Schaftingen, V. Stroobant, 2012, The Journal of Biological Chemistry.